Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. immorist

ImMoRiSt

Immune Monitoring for RIsk STratification in Solid Organ Transplant Recipients

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0
 Outcomes and results

 ImMoRiSt project word cloud

Explore the words cloud of the ImMoRiSt project. It provides you a very rough idea of what is the project "ImMoRiSt" about.

triggered    ce    logical    final    leader    relatively    24    validation    solid    regulatory    rejection    scan    switzerland    outcome    patients    provides    freedom    release    patient    kidney    selectively    blood    function    approval    monitoring    gamma    marking    ifn    strategy    transplantation    heart    proprietary    clinically    diagnostic    mediated    global    cells    centers    quantitative    operate    immune    highest    complications    organ    right    feasibility    qualitative    performed    immunosuppressive    links    frequency    lophius    stimulants    ivd    caused    biosciences    business    lung    cocktail    transplanted    clinical    obtain    recipients    physicians    liver    transplant    drugs    grow    immunomonitoring    interferon    tests    stimulate    yield    parallel    infections    uses    functional    pursued    dosage    strength    plan    setting    place    obtaining    sot    biomarker    validate    germany    entry    improves    every    cell    explore    austria    firm    market    competitor    detection    suited   

Project "ImMoRiSt" data sheet

The following table provides information about the project.

Coordinator		 LOPHIUS BIOSCIENCES GMBH 

Organization address
address: AM BIOPARK 13
city: REGENSBURG
postcode: 93053
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Germany [DE]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2015
 Funding Scheme SME-1
 Starting year 2016
 Duration (year-month-day) from 2016-02-01   to  2016-07-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    LOPHIUS BIOSCIENCES GMBH DE (REGENSBURG) coordinator 50˙000.00

Map

 Project objective

Every year ~ 40.000 patients throughout the EU are transplanted a new kidney, lung, liver, heart or another organ. The frequency of clinical complications is relatively high because at present there are no diagnostic tests that help physicians to determine the right dosage of immunosuppressive drugs necessary to avoid both organ rejection and clinical complications caused by infections.

Lophius Biosciences GmbH has developed I-Scan, a functional immune monitoring test that within 24 h provides important information on the strength of the immune system in solid organ transplant recipients. I-Scan uses a proprietary cocktail of stimulants that selectively stimulate the clinically relevant immune cells in a patient’s blood sample. The detection of the triggered interferon γ (IFN-γ) release provides a qualitative and quantitative measurement of cell-mediated immune function.

The feasibility study performed during Phase 1 will explore issues related to both, the clinical biomarker validation study and the best market entry strategy. Several objectives are pursued in parallel and encompass: • Setting up the business plan which includes a competitor as well as a freedom-to-operate analysis and a market entry strategy. • Selection of clinical study partners and defining the design of the clinical study, best suited to yield highest clinical evidence • Obtaining regulatory approval for the planned clinical study and setting a strategy to obtain regulatory approval / CE-Marking for final I-Scan products.

Lophius will apply for Phase 2 funding of a clinical study to validate that I-Scan improves the outcome of SOT patients. This study is likely to take place in Germany, Switzerland and Austria where Lophius has already established firm links to transplantation centers. The study is the logical next step to further grow Lophius to become a global leader in the IVD market for immunomonitoring

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "IMMORIST" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "IMMORIST" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

INADVANCE (2019)

Patient-centred pathways of early palliative care, supportive ecosystems and appraisal standard

Read More  

PREMSTEM (2020)

Brain injury in the premature born infant: stem cell regeneration research network

Read More  

INTE-AFRICA (2019)

Integrating and decentralising diabetes and hypertension services in Africa

Read More